Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 20/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.86 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.86 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.86 |
| ▸ | GLP1R | P43220 | 1/20 | 0.86 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.86 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.86 |
| ▸ | ADGRF1 | Q5T601 | 1/20 | 0.86 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.86 |
| ▸ | CNR2 | P34972 | 5/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1315434 | 0.93 | CNR1 (1.00) | CNR1ADRB2ADRA2AAGTR1GLP1R | |
| SCHEMBL5468091 | 0.91 | CNR1 (0.83) | CNR1ADRB2ADRA2AAGTR1GLP1R | |
| SCHEMBL5469436 | 0.91 | CNR1 (1.00) | CNR1ADRB2ADRA2AAGTR1GLP1R | |
| SCHEMBL5459428 | 0.91 | CNR1 (0.83) | CNR1ADRB2ADRA2AAGTR1GLP1R | |
| SCHEMBL5459855 | 0.85 | CNR1 (0.85) | CNR1ADRB2ADRA2AAGTR1GLP1R | |
| SCHEMBL1846007 | 0.84 | CNR1 (0.73) | CNR1ADRB2ADRA2AAGTR1GLP1R | |
| SCHEMBL5348509 | 0.83 | CNR1 (1.00) | CNR1ADRB2ADRA2AAGTR1GLP1R | |
| SCHEMBL5461341 | 0.83 | CNR1 (0.85) | CNR1ADRB2ADRA2AAGTR1GLP1R | |
| SCHEMBL5342711 | 0.81 | CNR1 (0.81) | CNR1ADRB2ADRA2AAGTR1GLP1R | |
| SCHEMBL5463031 | 0.81 | CNR1 (0.72) | CNR1ADRB2ADRA2AAGTR1GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7151097-B2 | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof | PFIZER INC. (US) | 2006-12-19 | — | — | US | claimed |
| EP-1682554-A1 | BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS AND USES THEREOF | Pfizer Products Incorporated (US) | 2006-07-26 | — | — | EP | claimed |
| WO-2005044822-A1 | BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2005-05-19 | — | — | WO | claimed |
| US-20050101592-A1 | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof | PFIZER INC. | 2005-05-12 | — | — | US | claimed |
| US-20070027133-A1 | BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS AND USES THEREOF | PFIZER INC | 2007-02-01 | — | — | US | disclosed |
| US-20070027133-A1 | BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS AND USES THEREOF | PFIZER INC | 2007-02-01 | — | — | US | disclosed |
| US-20070027133-A1 | BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS AND USES THEREOF | PFIZER INC | 2007-02-01 | — | — | US | disclosed |
| US-7151097-B2 | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof | PFIZER INC. (US) | 2006-12-19 | — | — | US | disclosed |
| EP-1682554-A1 | BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS AND USES THEREOF | Pfizer Products Incorporated (US) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005044822-A1 | BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2005-05-19 | — | — | WO | disclosed |
| US-20050101592-A1 | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof | PFIZER INC. | 2005-05-12 | — | — | US | disclosed |
| US-20050101592-A1 | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof | PFIZER INC. | 2005-05-12 | — | — | US | disclosed |
| US-20050101592-A1 | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof | PFIZER INC. | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027133-A1 | BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS AND USES THEREOF | CNR2, CNR1, GPR18 | CNR1 2/4885ADRB2 100/4885ADRA2A 244/4885 |
| US-20050101592-A1 | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof | CNR2, CNR1, GPR18 | CNR1 2/4885ADRB2 100/4885ADRA2A 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.